ResearcherSecond Military Medical UniversityActive in the last 2 years
Gang Y Jin
Matched on ORCID iD 0000-0002-0128-7395; OpenAlex author ID A5002603813. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 28
2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 5
- Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac axis invasion: A safe and effective surgi… Last author DOI 10.1016/j.surg.2024.109045↗
- A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-023-11181-x↗
- Identification and functional analysis of heterogeneous FOXP3+ Treg cell subpopulations in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.scib.2018.05.028↗
- Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer. Co-author DOI 10.1007/s10238-015-0401-2↗
- CD13hi Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2016.1258504↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shiwei Guo · 4 shared papers, 2017–2025 · strength 0.52
- Paper Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac a… DOI 10.1016/j.surg.2024.109045↗
- Paper A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-023-11181-x↗
- Paper Identification and functional analysis of heterogeneous FOXP3+ Treg cell subpopulations in human pancreatic ductal aden… DOI 10.1016/j.scib.2018.05.028↗
- Suizhi Gao · 2 shared papers, 2023–2025 · strength 0.37
- Lingyu Zhu · 2 shared papers, 2023–2025 · strength 0.37
- Xiaoyi Yin · 2 shared papers, 2023–2025 · strength 0.37
- Xiaohan Shi · 2 shared papers, 2023–2025 · strength 0.37
- Kailian Zheng · 1 shared paper, 2025 · strength 0.21
- Zhendong Fu · 1 shared paper, 2025 · strength 0.21
- Meilong Shi · 1 shared paper, 2025 · strength 0.21
- Shuo Shen · 1 shared paper, 2023 · strength 0.16
- Jian Wang · 1 shared paper, 2023 · strength 0.16
- Guoxiao Zhang · 1 shared paper, 2023 · strength 0.16
- Hui Jiang · 1 shared paper, 2023 · strength 0.16
- Wenyu Liu · 1 shared paper, 2018 · strength 0.09
- Gang Yi · 1 shared paper, 2018 · strength 0.09
- Bin Li · 1 shared paper, 2018 · strength 0.09
- Chunfang Gao · 1 shared paper, 2017 · strength 0.07
- Weiping Ji · 1 shared paper, 2017 · strength 0.07
- Yunpeng Zhao · 1 shared paper, 2017 · strength 0.07
- Pingting Zhou · 1 shared paper, 2017 · strength 0.07
- Xiongfei Xu · 1 shared paper, 2017 · strength 0.06
- Chenyan Zhao · 1 shared paper, 2017 · strength 0.06
- Min Shi · 1 shared paper, 2017 · strength 0.06
- Biao Yang · 1 shared paper, 2017 · strength 0.06
- Jing Zhang · 1 shared paper, 2017 · strength 0.06
- Ying Chen · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.